4d Pharma Research Limited

The Rowett Research Institute

The University Court of the University of Aberdeen

Cj Bioscience, Inc.

Denise Kelly

Imke Elisabeth Mulder

Angela Margaret Patterson

Edouard Monnais

The present invention relates toflagellin, and/or a polynucleotide sequence encoding saidflagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.

Polypeptide and immune modulation

A first aspect of the invention relates to the bacterial speciesfor use in: regulating the immune system of a subject treating an immune disorder; treating an intestinal disorder; improving intestinal microbiota; regulating the innate immune system of a subject; regulating the adaptive immune system of a subject; regulating appetite in a subject; promoting Tregs and immune tolerance; promoting gut health in a subject; and/or maintaining immune homeostasis in a subject. Further aspects of the invention relate to compositions comprising

Bacterium for use as a probiotic for nutritional and medical applications

A first aspect of the invention relates to a porcine lactic acid bacterial strain, wherein said bacterial strain is characterised by one or more of the following characteristics: (i) the ability to exhibit antimicrobial activity against; (ii) the ability to exhibit antimicrobial activity against; (iii) the ability to suppress inflammation in IPEC cells induced by 12-0-tetradecaboylphorbol-13-acetate (PMA); (iv) the ability to block the attachment or invasion of IPEC cells by; (v) the ability to block the attachment or invasion of IPEC cells by; (vi) the absence of antibiotic resistance to one or more antibiotics selected from the following: ampicillin; cefotaxime; chloramphenicol; erythromycin; gentamicin; tetracycline; vancomycin; metronizadole; nalidixic acid; and kanamycin; and (vii) the ability to exhibit heat stability when subjected to three cycles of heating, each cycle comprising heating at a temperature of 70&#xb0; C. for a period of 15 minutes. Further aspects of the invention relate to compositions comprising said bacterial strains, and therapeutic uses of said bacterial strains.

Lactic acid bacterial strains

The present invention relates to polypeptide HP, or a polynucleotide sequence encoding polypeptide HP, or a host cell comprising said polynucleotide sequence, or a host cell comprising an expression vector comprising said polynucleotide sequence, for use in the treatment and/or prevention of a disorder in a subject; wherein said disorder is an inflammatory disorder and/or an autoimmune disorder; wherein said polypeptide has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof; and wherein said polynucleotide sequence encodes a polypeptide which has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof and/or wherein said polynucleotide sequence has at least 75% identity to SEQ ID NO 1, SEQ ID NO 3 or SEQ ID NO 5 or variants, homologues, fragments or derivatives thereof.

Pirin polypeptide and immune modulation

Porcine lactic acid bacterial strains

[object Object]

Described herein are porcine lactic acid bacterial strain compositions and processes of obtaining porcine lactic acid bacterial strains. Further aspects of the invention relate to food additives, supplements and probiotic compositions comprising said bacterial strains, and therapeutic uses of said bacterial strain compositions.

The invention relates to an assay to select a candidate drug for the treatment of inflammatory disease due to cytokine production. The assay comprises: a) exposing said candidate drug to intestinal cells; and b) analysing the effect of the said candidate drug selected from the group consisting of the variation of nuclear export or import of transcription factors from the NF-&#x3ba;B family the disruption of transcriptional activity of transcription factors from the NF-&#x3ba;B family, the differential histone acetylation of p65 (RelA); the variation of the amount of PPAR&#x3b3;/RelA complexes in the cytosol of the cells; and a combination thereof. The invention further relates to methods for the treatment of inflammatory cytokine production associated diseases and to the use of a therapeutically effective dose ofor a component thereof.

Methods for treating an inflammatory disease of the bowel

The present invention relates to a polypeptide growth factor derived from colostrum (CDGF) having defined chemical and biological characteristics. The factor may be prepared from porcine or bovine colostrum and pharmaceutical uses thereof may include combatting invasion of the body by pathogens, wound healing, promoting organ growth and development and promoting adaption of the gastrointestinal tract to diet change.

Growing community of inventors

Aberdeen, United Kingdom

Denise Kelly